HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK. Export

@article{citeulike:4380792, abstract = {We demonstrated that the prognosis of breast cancer patients who received adjuvant immunochemotherapy with Krestin (PSK) showed a tendency to be better than that of breast cancer patients receiving chemotherapy only. We retrospectively investigated the usefulness of HLA typing for selecting patients to receive adjuvant immuno-chemotherapy with PSK. One hundred and thirty-four patients with operable breast cancer were typed as HLA-A, -B, -C by a lymphocytotoxicity test. Patients without vascular invasion had no adjuvant therapy (NA group). Patients with vascular invasion in the tumor and/or in the metastatic lymph node were randomized into two groups. In group 1 (FEMP only), a combination chemotherapy of 100 mg of 5-fluorouracil (F), 50 mg of cyclophosphamide (E), 2 mg of mitomycin C (M), and 5 mg of predonisolone (P) was orally administered daily for 28 days (one course). In group 2 (FEMP+PSK), FEMP and 3.0 g of PSK were orally administered for 28 days (one course). Two courses a year of these agents were given for five years in both groups. Each group (NA, FEMP, FEMP+PSK) was stratified by the presence of HLA B40 type (B40(+)) or not (B40(-)). Five- and 10-year disease-free survival (DFS) rates (93\%, 80\%, respectively) of patients with B40(+) seemed to be better than those (83\% and 51\%) of patients with B40(-). In the NA group, 5- and 10-year DFS were 100\% and 71\% in patients with B40(+), 92\% and 76\% in those with B40(-), respectively. In the FEMP group (chemotherapy only), 5- and 10-year DFS of patients with B40(+) were both 84\%. These were not statistically significant compared with those (82\% and 33\%) of patients with B40(-). On the other hand, in the FEMP+PSK group, 5- and 10-year DFS of patients with B40(+) were both 100\%, and those of patients with B40(-) were 76\% and 55\%, respectively. DFS of patients with B40(+) was significantly better than that of patients with B40(-). It is concluded that HLA typing may be a predictive index in determining the use of immunochemotherapy combined with PSK for patients with operable breast cancer.}, author = {Yokoe, T. and Iino, Y. and Takei, H. and Horiguchi, J. and Koibuchi, Y. and Maemura, M. and Ohwada, S. and Morishita, Y.}, citeulike-article-id = {4380792}, citeulike-linkout-0 = {http://view.ncbi.nlm.nih.gov/pubmed/9252721}, citeulike-linkout-1 = {http://www.hubmed.org/display.cgi?uids=9252721}, issn = {0250-7005}, journal = {Anticancer research}, keywords = {breast, breastcancer, cancer, chemotherapy, hla, krestin, polysaccharide, progressionfreesurvival, psk, retrospective, survival}, number = {4A}, pages = {2815--2818}, posted-at = {2009-04-22 22:40:16}, priority = {2}, title = {HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/9252721}, volume = {17}, year = {1997} }

TY - JOUR ID - citeulike:4380792 L3 - citeulike-article-id:4380792 N2 - We demonstrated that the prognosis of breast cancer patients who received adjuvant immunochemotherapy with Krestin (PSK) showed a tendency to be better than that of breast cancer patients receiving chemotherapy only. We retrospectively investigated the usefulness of HLA typing for selecting patients to receive adjuvant immuno-chemotherapy with PSK. One hundred and thirty-four patients with operable breast cancer were typed as HLA-A, -B, -C by a lymphocytotoxicity test. Patients without vascular invasion had no adjuvant therapy (NA group). Patients with vascular invasion in the tumor and/or in the metastatic lymph node were randomized into two groups. In group 1 (FEMP only), a combination chemotherapy of 100 mg of 5-fluorouracil (F), 50 mg of cyclophosphamide (E), 2 mg of mitomycin C (M), and 5 mg of predonisolone (P) was orally administered daily for 28 days (one course). In group 2 (FEMP+PSK), FEMP and 3.0 g of PSK were orally administered for 28 days (one course). Two courses a year of these agents were given for five years in both groups. Each group (NA, FEMP, FEMP+PSK) was stratified by the presence of HLA B40 type (B40(+)) or not (B40(-)). Five- and 10-year disease-free survival (DFS) rates (93%, 80%, respectively) of patients with B40(+) seemed to be better than those (83% and 51%) of patients with B40(-). In the NA group, 5- and 10-year DFS were 100% and 71% in patients with B40(+), 92% and 76% in those with B40(-), respectively. In the FEMP group (chemotherapy only), 5- and 10-year DFS of patients with B40(+) were both 84%. These were not statistically significant compared with those (82% and 33%) of patients with B40(-). On the other hand, in the FEMP+PSK group, 5- and 10-year DFS of patients with B40(+) were both 100%, and those of patients with B40(-) were 76% and 55%, respectively. DFS of patients with B40(+) was significantly better than that of patients with B40(-). It is concluded that HLA typing may be a predictive index in determining the use of immunochemotherapy combined with PSK for patients with operable breast cancer. IS - 4A JF - Anticancer research SN - 0250-7005 EP - 2818 TI - HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK. VL - 17 SP - 2815 KW - breast KW - breastcancer KW - cancer KW - chemotherapy KW - hla KW - krestin KW - polysaccharide KW - progressionfreesurvival KW - psk KW - retrospective KW - survival AU - Yokoe, T AU - Iino, Y AU - Takei, H AU - Horiguchi, J AU - Koibuchi, Y AU - Maemura, M AU - Ohwada, S AU - Morishita, Y PY - 1997///g UR - http://view.ncbi.nlm.nih.gov/pubmed/9252721 ER -